17th Dec 2015 16:11
LONDON (Alliance News) - FastForward Innovations Ltd and Port Erin Biopharma Investments Ltd on Thursday took note after Diabetic Boot Co Ltd received approval to market PulseFlowDF in the US.
Port Erin recently acquired 7,105 shares in DBC, while FastForward owns a 4.9% stake.
PulseFlowDF is being developed for the treatment of diabetic foot ulcers.
It won approval from the US Food and Drug Administration.
Shares in FastForward were up 2.2% at 6.90 pence on Thursday afternoon, while shares in Port Erin were untraded at 6.50p.
By Samuel Agini; [email protected]; @samuelagini
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
PEBI.L